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Editorial
Is hypertension the new HIV epidemic?
At first sight, this seems a ridiculous, crassly attention-
grabbing assertion. HIV infection is a sexually transmitted
infectious disease; hypertension is neither of these things.
HIV is a major global health priority and is recognized as a
serious threat to public health and development in many
poorer countries. Hypertension is seen as a disease of the
West, of prosperity and therefore of little relevance to
poorer countries. Yet, these two conditions have a number
of important things in common.
Hypertension and HIV infection are both mostly
asymptomatic, but can lead to fatal and disabling illness. It
is estimated that in 2013 hypertension was responsible for
at least 45% of deaths due to heart disease and 51% of
deaths due to stroke.1 Between 2000 and 2013, the number
of deaths attributable to hypertension rose from 7.6 to 9.4
million.2,3 Projections based on available data indicate that
the number of deaths attributable to hypertension over the
next 20 years may well exceed substantially the number re-
sulting from HIV/AIDS. This is not just true on a global
scale, but for most low- and middle-income countries. In
Africa, the global burden of disease attributable to non-
communicable disease is projected to increase by 27% over
the next 10 years.4
Hypertension and HIV are both quite easily diagnosed
through simple screening tests, particularly so with hyper-
tension. Thanks to the roll-out of antiretroviral drugs, HIV
is becoming a chronic health condition which can be man-
aged through a combination of drug therapies and lifestyle
change. This is also true for hypertension, and effective
drugs are generally cheap and easily administered. From a
health services perspective, chronic HIV infection and
hypertension pose very similar challenges: they share the
need for life-long treatment, regular monitoring and a reli-
able drug supply. As such, they require a major reorienta-
tion for health systems that are generally geared towards
dealing with acute rather than chronic problems.
For Africa as a whole, WHO estimates that antiretro-
viral therapies (ARTs) are now provided to over half the
population who are eligible.5 By contrast, new WHO data
for Ghana and South Africa show that less than 10%
of people with hypertension had access to effective treat-
ment.6 One reason for low treatment rates is that, as with
HIV/AIDS, the asymptomatic nature of hypertension
means most people living with the condition remain un-
aware of it until major pathological damage has happened.
For example, a recent systematic review of hypertension
studies for Africa found awareness ranged from 10% in
Ghana to only 8% in Gabon.7
In the early stages of the pandemic, HIV was not a con-
dition associated with poor countries, but that perception
quickly changed. Similarly, the view persists that hyperten-
sion is mainly a disease of the West, despite the growing
body of evidence that prevalences in poorer countries are
quickly catching up. Indeed, in some cases they are already
higher than in the West. As with HIV, South Africa has
one of the highest rates of hypertension anywhere in the
world.6 And as in the early stages of the HIV pandemic,
the rapid spread of hypertension to rural areas in poor
countries8 comes as a surprise. Risk factors associated with
hypertension such as obesity, lack of physical exercise and
unhealthy nutrition are believed to be urban problems in
low-income countries. Yet, prevalences of hypertension in
rural districts are already high9,10 and in some cases have
fully caught up to urban levels.11 Whereas hypertension is
not an infectious disease, the risky behaviours associated
with it are spreading fast and seem to be as effectively
transmitted as infectious agents. The classical divide
between urban and rural areas is fast becoming blurred.
HIV was faced with political denial and public misun-
derstanding in the early years of the pandemic, especially
in some poorer countries. There is a similar pattern of de-
nial with hypertension. Worryingly, this can also be seen at
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the international level: hypertension and associated cardio-
vascular conditions accounted for less than 3% of global
health assistance between 2001 and 2008.12 This denial is
based on the misguided view that hypertension does not af-
fect poorer social groups. Yet there is substantial evidence
that hypertension is highly prevalent among poorer groups
and that they are less likely to have access to effective treat-
ment.6 As with HIV, hypertension can be both a cause and
a consequence of poverty. For example, a national survey
in China found that 37% of patients and their families fell
below a US$1-a-day poverty line within 3 months of expe-
riencing stroke.13
Rather than being understood as a condition of poverty,
HIV remains a highly stigmatized condition and continues
to be blamed on irresponsible personal behaviour. To
some extent the same is true of hypertension, which is cau-
sally linked with behavioural factors such as obesity, high
salt intake and alcohol consumption and tends to cluster
with other risk factors—smoking, physical inactivity—for
cardiovascular disease. In the West it is increasingly recog-
nized that explaining these behaviours in terms of individ-
uals’ moral shortcomings is unhelpful and misses the
bigger picture of structural and environmental causes.
There is less evidence of this enlightened approach among
policy-makers in poorer countries or in international agen-
cies, who struggle to persuade funders and taxpayers to
help people who ‘eat and smoke too much’.
The 2011 UN Assembly of Heads of States noted with
concern that ‘the rapidly growing magnitude of non-com-
municable diseases (NCDs) affects people of all ages, gen-
der, race and income levels, and…that poor populations
and those living in vulnerable situations, in particular in
developing countries bear a disproportionate burden’.14
Several developing countries have set up national NCD
control programmes, but most of these remain a low prior-
ity and implementation creeps along with frustrating slow-
ness: a situation very reminiscent of the slow build-up of
AIDS control programmes in developing countries prior to
1990.
Recent editions of IJE have featured a debate about
the extent to which global health policy priorities
should shift from infectious diseases such as HIV to
non-communicable diseases such as hypertension.15–23
This debate has mainly pivoted on a social gradient
‘beauty contest’, disputing the pace at which conditions
such as hypertension are spreading to relatively poorer
groups. As argued by Remais et al. in IJE, rather than
framing policy as a choice between competing priorities,
the key challenge is to roll out services and interven-
tions which address both.24 At the same time, it has
been suggested that valuable lessons regarding hyperten-
sion could be taken from HIV/AIDS policies.25 Yet there
is little indication that these lessons are being taken on
board. Our response to the global epidemic of hyperten-
sion seems little better than our response to HIV/AIDS
two decades ago: too little too late. Can we not wake
up earlier this time, before millions have died?
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